TD Cowen’s 46th Annual Health Care Conference - Vertex Participation

Vertex Pharmaceuticals stands at a key inflection point in early 2026, evolving beyond its dominance in cystic fibrosis treatments into a broader biotechnology player with imminent catalysts in non-CF areas, particularly kidney diseases.

The primary driver of current relevance is povetacicept's progress toward potential U.S. accelerated approval in IgA nephropathy (IgAN), a progressive autoimmune kidney disorder that leads to proteinuria, hematuria, declining kidney function, and often end-stage renal disease. Vertex began the rolling BLA submission in Q4 2025 and expects to complete it in the first half of 2026, leveraging a priority review voucher for a six-month FDA review and Breakthrough Therapy Designation. This follows strong Phase 2 results showing meaningful reductions in key biomarkers and stable eGFR, with the Phase 3 RAINIER trial fully enrolled since late 2025. IgAN affects an estimated 330,000 people in the U.S. and Europe (over 1.5 million globally diagnosed), where existing therapies slow but rarely stop progression.

This renal focus addresses a critical unmet need and positions Vertex to diversify revenue streams. The company's February 2026 earnings reported 2025 full-year revenue of $12.0 billion (up 9%), with 2026 guidance at $12.95–13.1 billion, including at least $500 million from non-CF products like CASGEVY (gene therapy for sickle cell and beta thalassemia, with accelerating infusions) and JOURNAVX (acute pain treatment, gaining traction in its second year).

CF remains a growth engine through ALYFTREK rollout, younger-patient expansions, and next-generation candidates, but the non-CF pipeline—including povetacicept expansions into primary membranous nephropathy and myasthenia gravis, plus inaxaplin data readouts—signals sustained momentum. Analyst upgrades in February 2026 (e.g., Oppenheimer citing renal upside) underscore investor focus on these near-term value drivers amid broader biotech sector dynamics.